high-throughput screening Heart disease
cardiac microtissue
high-throughput screening approach
cardiovascular disease
development of microtissue
complex disease mutation
utilization of iPSC
developed microtissue
high-content screens
iPS-disease modeling potential
maturation of iPSC
physiological implication
models
Cardiac micro-engineered tissue
superior physiological relevance
novel therapeutic interventions
novel therapeutic targets
relevant physiological traits
state-of-the-art cardiac tissue engineering principles
patient care
pharmacological responses
development of induced
plate format
pharmacological treatments
significant cause of morbidity
current format centers
pluripotent stem cells
attempt
drug therapy
mortality
technology
society
phospholamban
PLN
lack of phenotypic cardiomcyoytes maturity
death
year
loss
industrialized world
R14del
EU economy
huge burden
European Union
cardiotoxicity of drugs
productivity
limitation
derived cardiomyocytes
dish
setting
cure
latest advances
research
pathology
creation
aim of CAMEOS
prevalence